HIGHLIGHTS
- who: Zhen Lu et al. from the DepartmentUniversity of Houston, Texas, USA have published the paper: SIK2 inhibition enhances PARP inhibitor activity breast cancers, in the Journal: (JOURNAL)
- what: This study has a number of limitations. The aim of this study was to define the effect of SIK2 inhibitors (ARN3236 and ARN3261) on cancer cell growth in ovarian cancer and TNBC as well as to explore mechanisms underlying the synergy between SIK2 and PARP inhibition.
- how: The authors hypothesized that SIK2 inhibition may block MEF transcription factor activity. Next the authors examined whether . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.